• 150年来西班牙知识产权领域的领航者

  • 艾萨博睿第8届年度大会

    艾萨博睿第8届年度大会

    10/04/2015 - Espacio CÓMO

  • Leaders in intangible asset management and legal advisory services

  • We defend authors, artists, and makers of all intellectual creations

  • Different paths, different countries, … different solutions

最新消息



Elzaburu 150 years


Elzaburu in Busines TV

新闻

Blog

  • New judgment by the CJEU concerning SPCs for combinations of pharmaceutical products
    The Court of Justice of the European Union has issued new judgment interpreting Articles 1, 3, and 13 of Regulation (EC) No. 469/2009 concerning the supplementary protection certificate (SCP) for medicinal products.

    The judgment (Case C-577/13) was issued in the context of a dispute between the Actavis and Boehringer Ingelheim pharmaceutical companies. The question referred to the CJEU for a preliminary ruling basically comes down to whether an SPC may be sought for a combination of two products included in the claims after the initial grant of the basic patent, subsequent to amendment of the said patent. The combination was composed of: (i) an active ingredient claimed as the sole subject matter of the invention, for which the holder had already obtained a first SPC (telmisartan) and (ii) a second substance (hydrochlorothiazide) within the public domain.

    New judgment by the CJEU concerning SPCs for combinations of pharmaceutical products

    The Court of Justice of the European Union has issued new judgment interpreting Articles 1, 3, and 13 of Regulation (EC) No. 469/2009 concerning the supplementary protection certificate (SCP) for medicinal products.

    The judgment (Case C-577/13) was issued in the context of a dispute between the Actavis and Boehringer Ingelheim pharmaceutical companies. The question referred to the CJEU for a preliminary ruling basically comes down to whether an SPC may be sought for a combination of two products included in the claims after the initial grant of the basic patent, subsequent to amendment of the said patent. The combination was composed of: (i) an active ingredient claimed as the sole subject matter of the invention, for which the holder had already obtained a first SPC (telmisartan) and (ii) a second substance (hydrochlorothiazide) within the public domain.

    “谷歌税”真的改变了西班牙的市场吗?

    三个月前的今天谷歌新闻退出西班牙市场,而这一切都是源自于一个饱受争议的西班牙知识产权法案修订案增加了一项新关于从西班牙新闻报纸中索引内容的新闻聚合服务的规定。

    大众对此项规定的反应不尽相同,一些人持有强烈的反对态度,另外一些人则非常支持。双方各有各的依据,但是反对该项新规定的仍在多数。现如今,很难在谷歌西班牙搜索结果的前几页上看到任何网站支持“谷歌税”。 

    Weibo

    banner_marcathlon_2015_animado

    © ELZABURU 2015 - Miguel Ángel, 21 - 28010 Madrid, España (Spain)  - Teléfono: +34-91 700 9400 - Fax: +34-91 319 3810 - elzaburu@elzaburu.es

    We have published a new Cookies Policy explaining what Cookies are and how we use them on our Website. We use third-party Cookies to analyse user browsing and predetermine the user's language. If you wish to know more about Cookies, their functions and/or disable them, please read our Cookies Policy. Bear in mind that some parts of the Website will not function correctly if Cookies are disabled.
    By continuing to use this Website, you are consenting to the use of Cookies.
    Depending on whether or not you consent to the use of cookies on this Website, you will be sent an additional Cookie so that your choice is remembered and you do not have to accept the use of Cookies every time you access the Elzanet Website.